



EPIGENOME ENGINEERING: UNDERSTANDING, MANAGING, AND IMPROVING TECHNICAL ASPECTS

Ahmad Mohammad Khalil^{1*}

1. Department of Biological Sciences, Yarmouk University, Irbid, Jordan.

ARTICLE INFO

Received:

02 Apr 2023

Received in revised form:

09 Jun 2023

Accepted:

12 Jun 2023

Available online:

28 Jun 2023

Keywords: Epigenetics, Epigenome, Genome, Genomics, Gene expression

ABSTRACT

An epigenomic analysis is big data science, presenting tremendous challenges in its translation into knowledge. To exert precise spatiotemporal control of gene activation and repression, one must have a thorough grasp of the molecular building blocks of epigenetic processes. Only lately has the technology become available to adequately investigate the functional impact of intricate epigenetic pathways. This technology uses a combination of nuclease-null genome-editing (GE) systems and effector domains. Modern epigenome editing (EpGE) modular systems can be adapted to permit precise manipulation of epigenetic marks with no changes in underlying DNA sequence. This review briefly presents the currently achievable epigenetic manipulations along with matching applications in human food and health. The emerging era of Clustered regularly interspaced short palindromic repeats (CRISPR) EpGEs could perhaps be a game-changer for the management of chromatin and epigenetic signature an appealing strategy for therapeutic and breeding purposes. This nascent field is still suffering certain pitfalls.

This is an *open-access* article distributed under the terms of the [Creative Commons Attribution-Non Commercial-Share Alike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, and build upon the work non commercially.

To Cite This Article: Khalil AM. Epigenome Engineering: Understanding, Managing, and Improving Technical Aspects. *Pharmacophore*. 2023;14(3):119-30. <https://doi.org/10.51847/vv4pyDATfP>

Introduction

The term “genome” refers to all the genetic material for an organism including humans. On the other hand, the term “epigenetics”, is a literal translation of “on top of the genetics”. Fundamentally, the science of “epigenomics” refers to the record of the modifications in the nuclear architecture, DNA, and histone proteins of an organism. It focuses on examining the impact of chromatin topology, including higher-order chromatin folding and association with the nuclear matrix, DNA wrapping around nucleosomes, covalent modifications of histone tails (acetylation, methylation, phosphorylation, and ubiquitination), and DNA methylation (DM), on a cell's genetic makeup. The concept of epigenetics evolved with time and recent investigations at the molecular level mainly covered non-coding RNAs (ncRNAs) (**Figure 1**).




Figure 1. Mutual interaction of genetics, epigenetics, and environments to produce a normal or an abnormal phenotype. (Adapted from [1, 2])

These modifications occur typically at multiple sites collectively known as histone post-translational modifications. Added to this are the modification of DNA bases in some CpG-rich regions, and the expression of regulatory ncRNA molecules. In recent years, scientists made great steps in clarifying the functional roles of epigenetic processes.

Variations in the structure of chromatin may result from changes to the epigenome, which may then influence how the genome functions [3]. The epigenome controls how genes are expressed, how tissues develop, and how development proceeds. In contrast to the genome, which is kept generally fixed within an individual, the epigenome can be dynamically affected by environmental conditions.

Researchers have identified three different types of epigenetics [4] based on their spatial and temporal properties: a direct form of epigenetics (DE), two forms of indirect epigenetics (within indirect epigenetics (WIE) and across indirect epigenetics (AIE), and a third kind of indirect epigenetics. All of an individual's epigenetic changes that take place throughout the course of their lifetime are categorized as direct epigenetics. The same experience becomes an indirect environmental trigger for the ontogenetic growth of the new person when an epigenetic alteration caused by a direct experience is passed down to the offspring [4]. The whole set of synchronous epigenetic changes that affect the developing person is included in the WIE. Temporarily, it starts when the zygote develops and its surroundings start to change.

According to this fundamental tenet, environmental changes happen simultaneously with the existence of the proto-individual. Indirect epigenetics, which spans from the moment of conception back to the parents' and even grandparents' former lives, is the study of what happens [4]. The epigenomic changes may or may not be heritable. They can be passed down, independently of DNA sequence, from one generation to another through transgenerational stranded epigenetic inheritance. This mode of inheritance refers to the transmission of epigenetic tags, through generations, that influence the traits of offspring without changing the primary DNA structure [5]. Due to the action of the maintenance DNA methyltransferases (DNMTs), a type of post-replication alteration called DNA methylation (DM) can be passed down via cell division [6]. These enzymes create 5 mC by transferring a methyl group from S-adenyl methionine to a cytosine ring's fifth carbon. Demethylation, the opposite process, can be passive or active and is more difficult. TET enzymes oxidize 5 mCs and aid in the elimination of DM from a specific locus [5, 7]. The methylation of DNA and histones induces down-regulation of gene expression, while histone acetylation and phosphorylation enhance gene expression [8]. According to yeast the memory of DM may last for millions of years [5], indicating that daughter cells may get a gene expression profile from parental cells (a process known as "cellular memory") or at the generational level when a parent passes on a trait to its children.

Biotechnologies that attempt to modify endogenous, site-specific epigenetic targets are responsible for this advancement. Despite recent progress, significant work has to be done to fully understand how epigenetic pathways affect cellular programming, illness, and tailored therapy.

The speed of epigenetic research picked up drastically from the early 2000s. **Figure 2** demonstrates that between 2000 and 2010 the number of published articles found in the database that had the word 'epigenetics' in their title grew up to 1000. The public prominence of epigenetics increased with the launching of the Human Epigenome Project. By 2015, the main information about functional basics that control gene expression in about 127 human tissues and cell types was disclosed. By that time the figure of available research papers jumped to about 3000. Following this, the number of published epigenetics papers mushroomed, so it is hard to keep up. Numerous diagnostic and pharmaceutical corporations were also developing tests and candidate epi-drugs [7]. Just how far the area progressed can be realized from the statistics that in 2016 experts from Grand View Research forecasted that the global business market for epigenetic products would reach USD 16.31 billion by 2022.




Figure 2. Search results of epigenetic publications per year by each keyword in PubMed and the database of ISI Web of Knowledge.

Materials and Methods

This survey was based on screening the recent literature up to July 2023 using PubMed and the database of ISI Web of Knowledge. The keywords used for the search were ("Epigenetics"), ("Epigenome editing"), ("Genome editing"), ("Functional genomics"), ("Gene expression"), and ("CRISPR/Cas9"). After the exclusion of duplications and non-English publications, a

total of 80 articles were selected. These papers were analyzed and reviewed to (1) list and define the EpGE architecture and approaches, (2) assess the applications of EpGE, and (3) present the challenges of EpGE and suggest alternate solutions. Only a single 2007- paper and another in 2010 were used to lay down the EpGE approaches, and the mechanisms regarding gene expression and regulation. There were 21 published between 2011 and 2018. Fifty-seven of the examined research works appeared during the years: 2019, 2020, 2021, 2022, and 2023.

Results and Discussion

The fundamentals of DNA-binding are the same in both GE and EpGE processes. However, EpGE techniques lack the endogenous DNA repair mechanisms that GE procedures provide. In contrast to GE, which modifies the actual DNA sequence itself, EpGE modifies and displays DNA sequences for proteins and other DNA-binding substances that influence DNA function.

Conceptually, EpGE utilizes the two main features of epigenetic marks: heritability and reversibility [9]. The first means that the epigenetic mark of DM and certain histone modifications are passed over generations. The second means that the cell can respond to external stimuli by adjusting these marks. The Epigenetic enzymes are considered the effectors of both maintaining and modifying epigenetic signatures. The proper epigenetic mark(s) assigned to effectively modify gene expression should be confirmed for any given chromatin context and must be (mitotically) stable. Rewriting an epigenetic mark can be done by epigenome editing to change how an organism's endogenous genes are expressed. A catalytic domain (CD), also known as an effector domain (ED), writer, or eraser, is directed to a particular locus with the goal of rewriting a gene's epigenetic imprint. The ED is fused to a programmable gene-specific DNA-binding domain (DBD) in order to do this; a linker peptide is employed to join a DBD and an ED. Writers are the enzymes in epigenetics that add the moiety to histone tails. Erasers delete epigenetic changes on a specific basis. In order to guarantee the existence of the proper histone modification to manage the required transcriptional program, writers and erasers coexist in harmony [10]. Dysregulation of one or both causes aberrant histone modifications, which alter transcription. A CD that allows the enzymatic reaction of moiety transfer to occur is required for all epigenetic writers, as is another domain that allows the identification of chromatin. For instance, HMT (the writer) transfers a methyl group onto definite lysine residues on histones. On the other hand, the Jumonji domain-containing histone demethylase (eraser) removes histone methylation by oxidation reactions.

Updated History of Epigenome Editing

Over the years, various EpGE tools were utilized to change DM at predetermined sites (**Figure 3**). With the help of the catalytically dead (CRISPR) associated Cas9, also known as dCas9, several research teams [11-13] have advanced technologies for targeted gene expression. These technologies include the zinc finger (ZF) and transcription-activator-like effector (TALEs) fusions. Since the CRISPR-dCas9 system is an RNA-guided DNA-targeting system, it has several advantages over ZFs and TALEs in terms of targeted gene activation.

This eliminates the requirement for intricate protein engineering and may create new opportunities for spatiotemporal control of gene expression. Researchers demonstrated the efficacy of using epigenetic effectors connected to DNA-targeting proteins to modulate epigenetic landscapes in addition to transcriptional activators for directed gene expression.

However, compared to TALE-based activators, several results revealed that dCas9-based activation tools cause lower amounts of transcription [12].




Figure 3. The evolution and application of epigenome editing tools. (a) The first site-specific DNA methylation tool was introduced in 1997. In this in vitro procedure, a bacterial methyl transferase (ED) was fused with ZF proteins

(ZFPs) to identify a nine-nucleotide DNA sequence. In 2002, a ZEP was also attached to CDs of HMT to edit histone 3 methylation of Lysine 9 (H3K9) methylation in vivo. (b) Then the CDs of DMT3a and Ten-eleven translocation hydroxylase or Lysine-specific demethylase 1 were fused TALE. (c) The dCRISPR-associated (Csa9), or dCas9, enormously extended the EpGE toolbox during the period 2015 to 2019. (d) Prospective expectation. (Adpted from 15, 16)

It was reported in 2015 that the p300 HAT CD has been modified using CRISPR-dCas9, TALE, and ZF fusions [13]. In order to cause the transactivation of genes, this places histone 3 lysine 27 (H3K27) and additional acetylation sites on histone tails (**Table 1**). In order to activate gene expression, other epigenetic effectors that catalyze covalent modifications in DNA have also been linked to DNA-binding proteins. As an illustration, TET demethylase enzymes were used with ZFs [14], TALEs [11], and CRISPR-dCas9 [15] to direct promoter-specific DNA demethylation and, consequently, upregulate gene expression. These enzymes catalyze the sequential oxidation of 5-methyl deoxycytosine (m5dC) to form 5-hydroxymethylcytosine, 5-formyl cytosine, and 5-carboxylcytosine.

Programmable Epigenome Editing Systems

Currently, three major sets of DNA-targeting proteins are largely employed in the EpGE system (**Table 1**) ZFPs, TALEs [16], and CRISPR [3, 17]. Epi-effectors consist of intended DNA recognition domains (ZF, TAL effector, or adapted CRISPR/Cas9 complex) and CDs from a chromatin-adjusting enzyme [18]. The CRISPR/dCas9 system is now the most extensively used platform because it takes less time and money to modify and implement the technology and because it is very effective and adaptable [19, 20].

Table 1. Summary of effector protein domains selected for epigenome editing systems and their effects on gene expression.

Chromatin/DNA Targeting Module	Effector Protein Domains*	Effects/Applications
ZFP	M. SssI (bacterial DNA methyltransferase)	DNA methylation in vitro
	SUV39H1 and G9A catalytic domains (histone methyltransferases)	Histone H3K9 methylation at the VEGF-A locus in cells
	G9A catalytic domain (histone methyltransferase) and p65 of NF-κB (to induce histone acetylation)	Histone modifications at FosB locus in nucleus accumbens of mouse brain
	Full length or the self-association domain of Ldb1 (transcription cofactor)	Induce chromatin looping at β-globin locus or fetal γ-globin locus
TALE	TET1 catalytic domain (Ten-eleven translocation methylcytosine dioxygenase)	DNA methylation in vivo
	DNMT3a catalytic domain and DNMT31 (mammalian DNA methyltransferase complex)	DNA methylation of CDKN2A gene in vivo
	LSD1 (histone demethylase)	histone H3K4 demethylation at multiple enhancers in vivo
SpdCas9	VPR	Transcriptional activation
dCpf1	VPR or p65	Transcriptional activation
SpdCas9	VP64 (VP16 tetramer)	Transcriptional activation
SpdCas9-SunTag	VP64 (VP16 tetramer)	Transcriptional activation and cellular reprogramming Can recruit p300 to deposit H3K27ac
SpdCas9	KRAB	Repression of transcription by blocking transcription complex formation.
	Mxi1	
	SID	May also recruit other repressive modifications
SpdCas9	DNMT3A full-length	Repression of transcription by DNA methylation in vivo
SpdCas9	DNMT3A catalytic domain	
SpdCas9-SunTag	DNMT3A full-length or catalytic domain	
SpdCas9	TET1 catalytic domain	Activation of transcription by DNA demethylation in vivo
SpdCas9-SunTag	TET1 catalytic domain	
SpdCas9	TET1 catalytic domain	
SpdCas9	G9a (EHMT)	Repression of transcription by targeting H3K9me
SpdCas9	SUV39H1 catalytic domain	
SpdCas9	LSD1	H3K4me2 demethylation
		Causes H3K27ac removal
		Both repress transcription.
		Ideal for enhancers

SpdCas9	p300 catalytic domain	Targeted H3K27ac
SpdCas9-SunTag	p300 catalytic domain	Ideal for enhancers
dCas13	ADAR2	RNA editing
dCas13	Modified ADAR2	Conversion of adenosine to inosine Conversion of cytosine to uracil

*Effector domains that interact with dCas9 can be divided into two categories: (i) transcriptional regulators that sequentially Use other proteins, such as transcriptional cofactors, chromatin modifying enzymes, and chromatin remodeling complexes; and (ii) chromatin modifying enzymes as such that catalyze the removal or addition of epigenetic marks. For instance, two effective transcriptional regulators, the Krueppel-associated box (KRAB) domain and the herpes simplex VP16, or the substitutes, have been employed successfully to activate and inactivate gene expression, respectively. To add or delete chromatin marks from histones or DNA, a variety of chromatin modifiers were used. The development of the dCas9-SunTag system made it possible to simultaneously enroll several copies of the same effector or other transcriptional regulators at a target location. The creation of dCas13 enabled the control of RNA in addition to DNA and chromatin editing techniques. Histone acetyltransferase, P300 ADAR: RNA-specific adenosine deaminases; catalytic domain (CD); DNA methylation is DM. DNA methyltransferase (DNMT); HMT: histone methyltransferase; H3K4: lysine 4 methylation on histone 3; H3K27: lysine 27 methylation on histone 3; TA stands for transcriptional activation, while SpdCas9 stands for *Streptococcus pyogenes* dead Cas9; TET1 stands for ten-eleven translocation methylcytosine dioxygenase 1, VP16 stands for herpes simplex virus protein 16, and VP64 stands for four tandem copies of VP16. (Adapted from 15, 18)

CRISPR-Cas systems are DNA-encoded and RNA-guided, in contrast to ZF- and TALE-based systems, which rely on protein-DNA interactions to target precise genetic loci [21, 22]. By attaching epigenetic effectors to the dCas9 protein and focusing on regulating regions like promoters and enhancers, epigenome editing has proven to be more precise and effective [23]. Because they can avoid the need for intricate protein engineering to facilitate DNA detection, CRISPR-Cas systems are given significant advantages by this property [24]. Gene-targeted epigenome reprogramming has received a lot of attention since the invention of CRISPR/Cas [25]. The trans-activating CRISPR RNA (tracrRNA) and the CRISPR RNA (crRNA) form a chimera with the Cas9 nuclease in the well-studied type II CRISPR system. Single-guide RNA (sgRNA) is a common name for this hybrid [26]. The NGG-trinucleotide repeats, which are located upstream of a protospacer adjacent motif (PAM), are complementary target DNA sequences that the sgRNA uses to activate dCas9. The CRISPR/dCas9 system may be used to target practically any genomic location of interest by changing the sequence of the gRNA [27]. It's interesting to note that numerous loci can be addressed equally, allowing for efficient multiplexing. CRISPR-Cas9- based EpGE uses an engineered SpCas9 variant, which is purposefully stripped of its catalytic activity into a catalytically "dead" or deactivated Cas9 (dCas9). The dCas9 system was used to target epigenetic reprogramming to initiate site-specific DM. By merging the DNMT3a CD with the dCas9 protein, dCas9-DNMT3a can achieve targeted DM of a targeted zone as dictated by the present sgRNA [25, 28]. Likewise, dCas9 was combined with the catalytic core of the human acetyltransferase p300 (**Table 1**). The dCas9-p300 complex effectively catalyzes targeted acetylation of lysine 27 in histone H3 (H3K27) [29].

While a dCas9 fusion to a repression domain demonstrated the CRISPR-dCas9 system's capacity to use a heterochromatin-forming complex to mute gene expression, binding of dCas9 to an epigenetic effector that acetylates histone tail residues leads to transcriptional activation. This system exerts a positive or negative control on the expression of developmentally relevant genes, which can govern specific differentiation decisions and direct the differentiation status of the cell down desired pathways. It is possible to utilize CRISPR in conjunction with a dCas9 fusion protein to reversibly modify DNA and heritably suppress the expression of "most genes" [30, 31]. Generating versions that can target multiple effector domain copies to a single site and targeting epigenetic alterations that, in certain situations, may be transferred to the next generation without the targeting assembly are recent breakthroughs in evolving CRISPR-dCas, systems [22, 31]. Combining effector domains and targeting strategies to produce synergies that improve the system's performance. A method established to manipulate the differentiation state of human pluripotent stem cells (hPSC) [21] is another aspect of this. A CRISPR EGE variation known as FIRE-Cas9 enables undoing the alteration if something goes wrong.

Similar to how genes are activated, repressor domains, or epigenetic effectors, are combined with DNA-binding proteins to silence endogenous gene expression at specific loci. The KRAB repressor domain, which is highly conserved, is the one that is most commonly used to silence genes (**Table 1**). Through interactions between the KRAB-associated protein 1 corepressor and other factors that catalyze histone methylation and deacetylation, complexes that result in the development of heterochromatin is recruited, which facilitates KRAB repression. Strong inactivation from the promoter and from the proximal as well as the distal regulatory elements has been demonstrated by the attachment of KRAB to ZFPs [3], TALEs [3], and CRISPR-dCas9 [32].

Researchers have discovered that additional repressor domains, such as the major interaction domain (SID) [3] and Mxi1 [9], can effectively silence genes in addition to the KRAB repressor. When dCas9-KRAB and dCas9-Mxi1 were examined, it was shown that the Mxi1 fusion may cause roughly three times as much repression [9]. According to different research [3], TALE-SID repressors may suppress transcription 26% more than their TALE-KRAB counterparts. Additionally, four SID (SID4X) domains concatenated together and bound to DNA-binding proteins can provide greater repression than a single SID domain fusion [3]. This is comparable to the connecting of ZFPs and their VP64 tetrameric form to VP16 units, which are involved in the enrolment of chromatin-modifying factors that improve chromatin accessibility [3].

Epigenetic effectors may accurately catalyze particular alterations in histones and DNA that result in targeted epigenetic repression, in contrast to transcriptional repressors, which adequately attract heterochromatin-forming complexes to desired loci. At target promoter and enhancer zones, histone demethylases [3, 32], HMT [32], as well as DNMTs [15] with ZF, TALE, and CRISPR-dCas9 proteins showed substantial suppression efficacy rates.

RNA alterations have recently emerged as key posttranscriptional regulators of gene expression strategies [33]. Understanding the functional significance of RNA changes in regulating coding and non-coding RNA processing and function, which in turn systematically shapes certain gene expression patterns, is making significant strides. They have an impact on several biological functions, and many of these alterations must be precisely deposited in order for growth to proceed normally. The modulation of circadian rhythms, spermatogenesis, embryogenesis, DNA damage, stress response, pluripotency, and cell reprogramming are only a few of the physiological processes that m6A deposition in RNA is essential for [34]. The N6-methyladenosine (m6A) regulators are also tightly connected to either oncogenic or tumor-suppressive actions [35].

Applications

EpGE, utilizing an inducible mechanism, offers a wide range of possible applications in addition to being a formidable tool for addressing fundamental epigenetic concerns in basic research. It aims to hasten the development of solutions and applications for everyday problems, from breeding to medicinal ones [21, 35, 36]. In recent years, bioengineers have developed effective metabolic pathways for ethanol generation in algae or maize, leading to the development of sustainable and affordable sources of renewable energy. They succeeded in improving crops and farm animals, as well as in developing novel treatment approaches for inherited and acquired disorders-associated epi-mutations. In the next sections, two main proofs of concept studies demonstrating the application of EpGE are discussed.

Plant Epigenome Editing

Because the yield and quality improvement of vegetables and crops are attracting attention as they are a source of food security for humanity, research in the field of plant EpGE is appealing and accelerating rapidly. Currently, this technology is opening the door to developing horticulture. It is valuable to explore epimutations in a range of crop species while understanding the basic features of epigenetic regulation of agronomically key traits such as yield, quality, and increase resistance to drought, disease, and to other stress factors [16, 22, 36-40]. Additionally, epi mutagenesis and focused control of transcriptional regulation are employed to increase our understanding of the relationships between critical proteins, alter plant developmental phenotypes, and advance our understanding of how plants accumulate, retain, and utilize DM [22]. These proteins have an impact on several elements of RNA metabolism and other biological processes in plants, such as seed formation, growth of the leaves and roots, floral transitions, and fruit ripening (**Figure 4**). This involves an apparatus containing “writers” (methyltransferase complex components), separated by “erasers” (demethylases), and documented by “readers” (Proteins that connect with m6A). The readers are corporate with m6A-adjusted RNA and control RNA splicing, RNA stability, and 3' untranslated regions (3'UTR) handling [41].




Figure 4. Control of plant's growth and development by post-transcriptional changes using m6A, the most prevalent internal modification present in the mRNAs of all higher eukaryotes. Post-transcriptional alterations are controlled by diverse writer, eraser, and reader proteins that affect different plant developmental processes such as seed development, leaf, and root growth and floral transitions, and fruit ripening [42, 43].

The ZF-based EpGE applied to *A. thaliana* and *O. sativa*, as well as the TALE and dCas9-based tools in *A. thaliana* and *O. sativa*, respectively, are among the tools employed in plants [41]. Furthermore, a great number of EpGE approaches based on small RNAs are hired for regulating gene expression in *A. thaliana*, *Nicotiana benthamiana*, *O. sativa*, *Solanum tuberosum* and *Z. mays* [22, 39, 44]. For example, reports on the use of the RNA-directed DM (RdDM) containing transgenically generated exogenous small interfering RNAs (siRNAs) in *A. thaliana* the RNAi-based tools in *O. sativa* [28, 41]. Moreover, tissue

culture-based EpGE DNA and/or histone modifications were accomplished in Caribbean agave *angustifolia*, Henequen (*A. fourcroydes*), *A. thaliana*, common tobacco (*N. tabacum*), *O. sativa*, *Pinus radiata*, *Z. mays* [44].

In addition to utilizing activator domains to directly activate transcription, another option is to use domains that can add active or remove restrictive epigenetic markers, indirectly activating gene expression. For instance, the p300 domain from humans have been used to target transcriptional activity in plants through H3K27 acetylation. Another method is to employ the CD of the plant-specific Arabidopsis HAT of the cAMP-responsive element-binding protein (CBP) Family 1 (HAC1). Although HAC1 can increase the transcription of targeted genes, using VP64 results in a higher amount of activation, at least for the gene p300 [45]. A highly efficient tactic is the combination of many distinct activator domains to cooperatively trigger gene expression [45, 46]. The stimulation of gene expression was boosted by VP128 to TAL activator domains being targeted directly. Additionally, the combination of VP64 with P65 and Rta (**Table 1**), two additional effectors domains that had previously been demonstrated to function in animals (VPR), was similarly capable of significantly increasing the amount of gene expression in plants compared to VP64 alone [45, 46].

For targeted gene repression in plants, the most frequently used EDs are the Arabidopsis ethylene response factor- associated amphiphilic repression domains, like those found in SUPERMAN or BODENLOS. These domains are used widely as a means to study highly redundant genes, since these repressor domains override activator domains, including VP16, and can be employed to turn a constitutive activator into a constitutive repressor [47]. Targeted addition of DM to promoters utilizing DNMTs is used fruitfully to repress transcription. For instance, the CD of the RdDM-based DNMTs from tobacco (*N. tabacum*), Domains Rearranged Methyl Transferase (DRM) can add DNA methylation to a target promoter, leading to transcriptional repression [48].

In addition to altering the epigenome for transcriptional repression, CRISPR interference (CRISPRi) is a direct method of suppressing gene expression by impeding RNA polymerase II activity. The use of CRISPRi has only been reported in plants, and only one instance of maize (*Z. mays*) has shown that CRISPRi can partially suppress a gene [43]. There are no studies on co-targeting several repressor domains to suppress transcription in plants [22].

Epigenome Editing in Medicine

Accumulating evidence proved that, relative to normal tissues, changes in the genome (genetic mutations), changes in the epigenome (epi-mutations), or both are intimately associated with the development and progression of human diseases, including cancers, type II diabetes mellitus, brain disorders, cardiovascular dysfunction, and even psychological disorders, to mention a few [8, 9, 14, 49, 50]. The epigenome, which serves as a link between the environment and the genome, is dynamically altered throughout the onset and development of many different diseases (**Figure 5**). By epigenomic sketching before the onset of diseases, it may become possible to tailor interferences to prevent chronic disorders or diseases in future life. Through the abundance of emerging signals signifying the involvement of epigenetic processes in the usual diseases, researchers tried to trace the epigenomic changes that can switch on or off genes implicated in cell growth or the immune response. Also, they attempted to use epigenetic biomarkers to detect new risk factors that might be linked to disease status.




Figure 5. Environmental factors, acting at various moments throughout the life cycle, can result in epigenetically-mediated alterations in gene expression and consequently in phenotype. Potential public health intervention may become reality. (The idea inspired from: [51]).

When adequate gene therapies have not yet been developed or are unsuitable, targeted regulation of disease-associated genes may allow for innovative treatments for a variety of disorders [18]. Although population-level and transgenerational consequences are not well understood, they may play a significant role in applied operational genomics and customized medicine [17]. Numerous epigenetic biomarkers and medicines have recently entered clinical trials for a variety of solid malignancies and have recently been licensed by the Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes and leukemias [35, 49]. It appears that various transcriptional activators produce gene expression at various intensities [3]. For targeted transcriptional activation, Farnesyl pyrophosphate synthase (FPPS) has also been linked

to transcriptional activator domains, such as the p65 component of the nuclear factor kappa B complex (Table 1). A well-known therapeutic target, the enzyme FPPS, is located in the mevalonate pathway. The subject of research is a recently discovered druggable pocket adjacent to the enzyme's active site [52]. Pharmacological modulation of this compartment is seen as promising, although its potential biological role is unknown at this time.

By concentrating on the maspin promoter region, researchers were able to revive a dormant mammary serine protease inhibitor (*maspin*) tumor suppressor gene [53]. In aggressive epithelial cancers, this gene is frequently epigenetically silenced. The ZFPs EpGE still has a bright future in treating many neurodegenerative illnesses [54]. A target gene's expression was reported to be boosted by five times or more when TALE activators were directed to the promoter region of the endogenous human vascular endothelial growth factor-A gene, which is up-regulated in many cancers and contributes to tumor angiogenesis [11]. Similar results showed that TALE fusions with the transcriptional activator VP64 boosted the endogenous levels of gene expression of a few human pluripotency factors by a ratio of two to five (Table 1). Combinations of TALE-VP64 fusions that target the promoter sites of genes associated with inflammatory, immunomodulatory, and cancer-related pathways established the presence of synergistic activation action at target areas, providing opportunities to build adjustable transcriptional networks. [11].

Figure 6 lists some diseases that would make good candidates for the development of innovative epigenetic therapies. Neurological illnesses may benefit from epigenetic editing. One of them is the fragile X syndrome, the most common kind of intellectual impairment in men, in which aberrant DNA methylation causes the FMR1 gene in neurons to be epigenetically silenced. Induced PSC-derived neurons once again expressed FMR1 after a precise demethylation of the FMR1 promoter using the dCas9-TET1 system flipped its heterochromatin status [55]. Another instance of a similar approach being successfully used to treat imprinting diseases, Prader-Willi (PWS) and Angelman (AS) syndromes, which are brought on by an abnormal DM fashion, was described [19].




Figure 6. Prospective therapeutic applications of EpGE. Different categories of disease could benefit from the development of discrete CRISPR/Cas9-driven EPGE strategies. Examples of how mutant or wild-type alleles could be maneuvered in specific disease contexts are depicted here. The molecular etiology underlying each disease class, as well as the dCas9 -based rescue strategy, are present [19].

Targeting (i) cytokines in the inflammatory pathway involved in treating degenerative disc disease [56] or (ii) cutaneous pain receptors [57] can be used to treat a variety of inflammatory and pain-related disorders. Surprisingly, because Olmsted syndrome and other autosomal dominant diseases are connected to the skin, it makes the skin an accessible and appealing organ for CRISPR-mediated gene silencing.

It was reported on the molecular basis for m6A deposition in RNA, variations in this deposition, biological function, and implications in a number of disorders, including cancer. It was also discussed how the presence of m6A, m5C, and pseudouridine (Ψ) in coding and non-coding RNAs plays a physiological and pathological function [32]. Changes in tRNA modifications, such as m5C or 5-methoxycarbonyl methyl uridine (mcm5U), have also been linked to cancer and are indicative

of altered protein translation [58].

EpGE, like RNA editing, excludes genetic modifications and the hazards connected with them [22]. Using CRISPR- dCas9 to suppress the expression of the gene SCN9A, which in human codes for a sodium ion channel, is an illustration of a potential functional use of EpGE. This approach revealed therapeutic possibilities in three mouse models of chronic pain [59]. Since the link between epigenetic alterations, their effects on gene expression, and the knowledge that these epigenetic changes are reversible have been established, new therapeutic avenues for the treatment of many diseases, including diabetes, cancer, and neurodegenerative illnesses, have become available [24].

Recent research [60] expressed its effectiveness in decreasing the levels of tau protein, a group of six protein isoforms involved in maintaining the stability of microtubules in the axons of the central nervous system [61]. These proteins control a protein involved in Huntington's disease, targeting an inherited form of obesity, and Dravet syndrome. It is understood that cancer is correlated with epigenetic changes, and hence CRISPR/Cas system displays capacity for cancer therapy using EpGE [8, 24, 54, 62]. By simultaneously turning on tumor suppressor genes and suppressing the production of oncogenes, this objective can be accomplished [63]. In this regard, simultaneous activation and repression of several genes in the same cell were achieved *in vitro* by combining dCas9 with chemically and photochemically inducible effector proteins [59] and by creating platform gRNA molecules that may use transcriptional regulators [59].

Limitations

Up until recently, comparative EpGE methods have shown a strong correlation between epigenomic traits and genome regulation. They do not, however, differentiate between the amount to which epigenetic circumstances actually cause gene activity states as opposed to merely correlating with them. These methods not only point out the drawbacks and technological restrictions but also imply that epigenetic markers do not have clear-cut purposes. Sequence specificity is decisively vital in EpGE therefore it must be wisely confirmed. EpGE faces the challenge of standardization for every new product, including finding an appropriate transformation vector and cloning the editing constructs with suitable genes and promoters. A significant limitation of the potential for EpGE as a biomedical plan in humans is the delivery of the system into the target cells. Several vehicles for the delivery of the large dCas9 fusion proteins to different types of target cells have been acknowledged [20, 26, 56, 64-69]. However, obstacles still prevent the widespread use of these tools for *in vivo* investigations. For example, delivery of the large dCas9 fusion proteins to different types of target cells and tissues is a hurdle to extensive implementation of these tools for *in vivo* studies [20, 26, 56, 64, 65].

Furthermore, it unclear if the TALE combination will have an impact on the epigenome modifier's catalytic activity. In effector proteins that require multiple subunits and multiplexes, this may be very important. The ligands and substrates at the target site maybe blocked by the proteins utilized in EpGE [44]. If they are directed to the same sequence, transcription factors themselves may compete with the TALE protein [51].

The vulnerability of the dCas9based EpGE systems to off-target effects, which can come from a variety of sources [70], is another issue. For instance, using a suboptimized sgRNA and a dCas9 enzyme domain fusion to initiate EpGE. The chromatin alterations might also be reversed by DNA repair mechanisms, preventing the desired modifications from developing. In plants, strategies related to the reduction of off-target mutations and the decrease in generation time also are important. Elimination of the editing reagents in plants may take manifold generations and therefore the developments in temporary expression are desirable. The accurate mapping of m6A changes at the level of cells may be aided by a variety of radical sequencing methods, including MeRIP-seq, immunoprecipitation, and miCLIP (m6A individual-nucleotide-resolution cross-linking) [49].

Conclusion

The ease with which GE and EpGE may be carried out has been significantly enhanced with the discovery, description, and adaptation of the CRISPR-Cas9 system. EpGE, facilitated by CRISPR/dCas9, develops a very effective targeted method for potential therapeutic applications in precision medicine. The CRISPR-Cas9 technology may be used in new ways to enable EpGE applications. Targeted gene activation or repression was made possible by the fusing of chromatin-modifying domains of dCas9 in both cultivated cells and *in vivo* animal models. Nevertheless, despite the substantial progress made in recent years to elucidate the molecular basis of epigenetic processes, EpGE is still a developing discipline that faces several problems and unanswered concerns. These limitations are related to off-target effects, editing efficiency, delivery, cytotoxicity, specificity, and stability of epigenetic states. It is anticipated that a conformationally activated CRISPR/Epi--editor, where the epigenetic enzymatic domains are functionally connected into one of the nuclease's domains of Cas9, will have more resolution and lower the off-target impact to potentially allow therapeutic uses in humans. Such off-target effects might be reduced by an inducible promoter that controls the interval and level of dCas9 fusion protein production.

In the clinical arena, where epigenomic medicine may have an impact, continuing, pre-clinical, and clinical trials are evaluating epidrugs individually or in combination with other pharmaceuticals. Overcoming the rising resistance and broadening the therapeutic profile outside hematological malignancies are the chief challenges faced by conventional epigenetic drugs. Thus, innovative approaches in the field of epigenetic treatment are urgently needed. Prior administration of an epi-drug, which can increase chromatin openness to chemotherapeutic drugs through chromatin decompaction, was suggested to make cells more sensitive to chemotherapy. The joint use of patient-derived iPSC and EpGE allows accurate disease modeling and investigations of the interconnection that epigenetic marks play in disease progression. Because of the intricacy of interactions, "programable" EpGE technologies are being created that may target or alter the epigenetic state at certain genomic loci,

allowing for the analysis of those loci's context-dependent function. Combinatory gene targeting strategies in cancer therapy will take a lot of hard work to develop effective delivery methods that can target the whole population of disease-associated cells. Considering the study that will be conducted in the upcoming years that focuses on scientific advancements in these sectors.

Finally, the discussion would be incomplete without mentioning some moral and ethical concerns that may result from the applications of EpGE. EpGE does not alter the genome directly, although it is currently believed to have less of an effect on germ cells than GE [71-74]. However, because of the probabilistic transgenerational epigenetic inheritance in methylation edited mammals [75-77], several questions and uncertainties about the health, safety, or other impacts of epi-engineered crops and foods have been raised [78].

Will scientists be able to spot epigenetic alterations brought on by possibly dangerous exposures in populations? Would these modifications act as a biomarker or signal of a higher chance of developing an illness in later life? What is the possibility of discrimination against people using social epigenetic data? Worldwide, there are calls for the adoption of policies that comprehensively regulate the use of private epi/genetic information for non-medical reasons by third parties.

Acknowledgments: None

Conflict of interest: None

Financial support: None

Ethics statement: None

References

1. Kesharwani RK, Tripathi S, Singh P, Kumari M, Atal SKV. The role of methylation in oncogene regulation. *Genom Bioinform.* 2020;3(1):161-31.
2. Khogeer AA, AboMansour IS, Mohammed DA. The role of genetics, epigenetics, and the environment in ASD: A Mini review. *Epigenomes* 2022;6(2):15.
3. Enríquez P. Epigenome Editing. In: Logie C, Knoch TA (eds). *Chromatin and Epigenetics*, 2018. doi:10.5772/intechopen.79564
4. Irene L, Rossella V. Epigenetic inheritance: Concepts, mechanisms, and perspectives. *Front Mol Neurosci.* 2018;11:292.
5. Kim M, Costello J. DNA methylation: An epigenetic mark of cellular memory. *Exp Mol Med.* 2017;49(4):e322.
6. Catania S, Dumesic PA, Pimentel H, Nasif A, Stoddard CI, Burke JE, et al. Evolutionary persistence of DNA methylation for millions of years after the ancient loss of a de novo methyltransferase. *Cell.* 2020;180(2):263-77.
7. Prado-Romero DL, Medina-Franco JL. Advances in the exploration of the epigenetic epigenetic-relevant chemical space. *ACS Omega.* 2021;6(35):22478-86.
8. Chakravarti R, Lenka SK, Gautam A, Singh R, Ravichandiran V, Roy S, et al. Review on CRISPR-mediated epigenome editing: A Future directive for therapeutic management of cancer. *Curr Drug Targets.* 2022;23(8):836-53.
9. Falahi F, Sgro A, Blancafort P. Epigenome engineering in cancer: Fairytale or a realistic path to the clinic? *Front Oncol.* 2015;5:22.
10. Yeo-Teh N, Ito Y, Jha S. Epigenetic actors: Key regulators targeted in cancers. In: Uchiumi F (ed). *Gene expression and regulation in mammalian cells - Transcription toward the establishment of novel therapeutics [Internet]*, IntechOpen, London. 2018:93. doi:10.5772/intechopen.73040
11. Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. *Nat Biotechnol.* 2013;31(12):1137-42.
12. Gao X, Tsang JC, Gaba F, Wu D, Lu L, Liu P. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in the regulation of gene expression by targeting enhancers. *Nucleic Acids Res.* 2014;42(20):e155.
13. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat Biotechnol.* 2015;33(5):510-17.
14. Liu XS, Jaenisch R. Editing the epigenome to tackle brain disorders. *Trends Neurosci.* 2019;42(12):861-70.
15. Huisman C, Van Der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K, et al. Re-expression of selected epigenetically silenced candidate tumor suppressor genes in cervical cancer by TET2-directed demethylation. *Mol Ther.* 2016;24(3):536-47.
16. Klug A. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. *Annu Rev Biochem.* 2010;79:213-31.
17. Laufer BI, Singh SM. Strategies for precision modulation of gene expression by epigenome editing: An overview. *Epigenetics Chromatin.* 2015;8(1):34.
18. Kungulovski G, Jeltsch A. Epigenome editing: State of the art, concepts, and perspectives. *Trends Genet.* 2016;3(2):101-13.

19. Policarpi C, Dabin J, Hackett JA. Epigenetic editing: Dissecting chromatin function in context. *BioEssays*. 2021;43(5):2000316.
20. Rittiner J, Cumaran Kumaran M, Malhotra S, Kantor B. Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of the next generation of the epigenetic drugs. *Front Bioeng Biotechnol*. 2022;10:1035543.
21. Khalil AM. The genome editing revolution: review. *J Genet Eng Biotechnol*. 2020;18(1):68.
22. Gardiner J, Ghoshal B, Wang M, Jacobsen SE. CRISPR–Cas-mediated transcriptional control and epi-mutagenesis. *Plant Physiol*. 2022;188(4):1811-24.
23. Guerra-Resendez RS, Hilton IB. Harnessing CRISPR-Cas9 for epigenetic engineering. *Methods Mol Biol*. 2022;2518:237-51.
24. Ansari I, Chaturvedi A, Chitkara D, Singh S. CRISPR/Cas mediated epigenome editing for cancer therapy. *Semin Cancer Biol*. 2022;83:570-83.
25. Rots MG, Jeltsch A. Editing the epigenome: Overview, open questions, and directions of future development. *Methods Mol Biol*. 2018;1767:3-18.
26. Syding LA, Nickl P, Kasperek P, Sedlacek R. CRISPR/Cas9 Epigenome editing potential for rare Imprinting imprinting diseases: A Review. *Cells*. 2020;9(4):993.
27. Babu K, Kathiresan V, Kumari P, Newsom S, Parameshwaran HP, Chen X, et al. Coordinated actions of Cas9 HNH and RuvC nuclease domains are regulated by the bridge helix and the target DNA sequence. *Biochemistry*. 2021;60(49):3783-800.
28. Gjaltema RAF, Rots MG. Advances of epigenetic editing. *Curr Opin Chem Biol*. 2020;57:75-81.
29. Cervantes-Gracia K, Gramalla-Schmitz A, Weischedel J, Chahwan R. APOBECs orchestrate genomic and epigenomic editing across health and disease. *Trends Genet*. 2021;37(11):1028-43.
30. Nakamura M, Gao Y, Dominguez AA, Qi LS. CRISPR technologies for precise epigenome editing. *Nat Cell Biol*. 2021;23(1):11-22.
31. Breunig CT, Köferle A, Neuner AM, Wiesbeck MF, Baumann V, Stricker SH. CRISPR tools for physiology and cell state changes: Potential of transcriptional engineering and epigenome editing. *Physiol Rev*. 2021;101(1):177-211.
32. Nombela P, Miguel-López B, Blanco S. The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities. *Mol Cancer*. 2021;20(1):18.
33. Mendel M, Chen KM, Homolka D, Gos P, Pandey RR, McCarthy AA, et al. Methylation of structured RNA by the m(6)A writer METTL16 is essential for mouse embryonic development. *Mol Cell*. 2018;71(6):986-1000.
34. Liu S, Li Q, Chen K, Zhang Q, Li G, Zhuo L, et al. The emerging molecular mechanism of m(6)A modulators in tumorigenesis and cancer progression. *Biomed Pharmacother*. 2020;27:110098.
35. Majchrzak-Celińska A, Warych A, Szoszkiewicz M. Novel approaches to epigenetic therapies: From drug combinations to epigenetic editing. *Genes*. 2021;12(2):208.
36. Shin H, Choi WL, Lim JY, Huh JH. Epigenome editing: targeted manipulation of epigenetic modifications in plants. *Genes Genom*. 2022;44(3):307-15.
37. Hou Q, Wan X. Epigenome and epi transcriptome: Potential resources for crop improvement. *Int J Mol Sci*. 2021;22(23):12912.
38. Singh D, Chaudhary P, Taunk J, Kumar Singh C, Sharma S, Singh VJ, et al. Plant epigenomics for extenuation of abiotic stresses: challenges and future perspectives. *J Exp Bot*. 2021;72(20):6836-55.
39. Hu J, Cai J, Xu T, Kang H. Epitranscriptomic mRNA modifications governing plant stress responses: Underlying mechanism and potential application. *Plant Biotechnol J*. 2022;20(12):2245-57.
40. Yang X, Patil S, Joshi S, Jamla M, Kumar V. Exploring epi transcriptomics for crop improvement and environmental stress tolerance. *Plant Physiol Biochem*. 2022;183:56-71.
41. Zheng H, Sun X, Li J, Song Y, Song J, Wang F, et al. Analysis of N6-methyladenosine reveals a new important mechanism regulating the salt tolerance of sweet sorghum. *Plant Sci*. 2021;304:110801.
42. Shoaib Y, Usman B, Kang H, Jung KH. Epitranscriptomics: An additional regulatory layer in plants' development and stress response. *Plants*. 2022;11(8):1033.
43. Zhou L, Gao G, Tang R, Wang W, Wang Y, Tian S, et al. m6A-mediated regulation of crop development and stress responses. *Plant Biotechnol J*. 2022;20(8):1-9.
44. Miglani GS, Kaur A, Kaur L. Plant gene expression control using genome- and epigenome-editing technologies. *J Crop Improv*. 2020;34(1):1-63.
45. Selma S, Bernabé-Orts JM, Vazquez-Vilar M, Diego-Martin B, Ajenjo M, Garcia-Carpintero V, et al. Strong gene activation in plants with genome-wide specificity using a new orthogonal CRISPR/Cas9-based programmable transcriptional activator. *Plant Biotechnol J*. 2019;17(9):1703-5.
46. Li Z, Zhang D, Xiong X, Yan B, Xie W, Sheen J, et al. A potent Cas9-derived gene activator for plant and mammalian cells. *Nat Plants*. 2017;3(12):930-6.
47. Kagale S, Rozwadowski K. EAR motif-mediated transcriptional repression in plants: an underlying mechanism for epigenetic regulation of gene expression. *Epigenetics*. 2011;6(2):141-6.

48. Papikian A, Liu W, Gallego-Bartolomé J, Jacobsen SE. Site-specific manipulation of Arabidopsis loci using CRISPR-Cas9 SunTag systems. *Nat Commun.* 2019;10(1):1-11.
49. Sarno F, Benincasa G, List M, Barabasi AL, Baumbach J, Ciardiello F, et al. Clinical epigenetics settings for cancer and cardiovascular diseases: Real-life applications of network medicine at the bedside. *Clin Epigenetics.* 2021;13(1):66.
50. Sarvari P, Sarvari P, Ramírez-Díaz I, Mahjoubi F, Rubio K. Advances of epigenetic biomarkers and epigenome editing for early diagnosis in breast cancer. *Int J Mol Sci.* 2022;23(17):9521.
51. Rozek LS, Dolinoy DC, Sartor MA, Omenn GS. Epigenetics: Relevance and implications for public health. *Annu Rev Public Health.* 2014;35(1):105-22.
52. Park J, Zielinski M, Magder A, Tsantrizos YS, Berghuis AM. Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product. *Nat Commun.* 2017;8(1):14132.
53. Beltran A, Parikh S, Liu Y, Cuevas B, Johnson GL, Futscher BW, et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. *Oncogene.* 2007;26(19):2791-8.
54. Ahmad A. Special Issue: Epigenetic regulation of cancer progression: Promises and progress. *Sem Cancer Biol.* 2022;83:1-3.
55. Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 Gene. *Cell.* 2018;172(5):979-92.
56. Farhang N, Ginley-Hidinger M, Berrett KC, Gertz J, Lawrence B, Bowles RD. Lentiviral CRISPR epigenome editing of inflammatory receptors as a gene therapy strategy for disc degeneration. *Hum Gene Ther.* 2019;30(9):1161-75.
57. Peirs C, Seal RP. Neural circuits for pain: Recent advances and current views. *Science.* 2016;354(6312):578-84.
58. Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. *Nature.* 2018;558(7711):605-9.
59. Moreno AM, Alemán F, Catroli GF, Hunt M, Hu M, Dailamy A, et al. Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice. *Sci Transl Med.* 2021;13(584):eaay9056.
60. Sexton C, Snyder H, Behr D, Boxer AL, Brannelly P, Brion J-P, et al. Current directions Directions in tau Tau research: Highlights from Tau 2020. *Alzheimer's Dement.* 2022;18(5):988-1007.
61. Sjölin K, Kultima K, Larsson A, Freyhult E, Zjukovskaja C, Alkass K, et al. Distribution of five clinically important neuroglial proteins in the human brain. *Mol Brain.* 2022;15(1):52.
62. Pacheco MB, Camilo V, Henrique R, Jerónimo C. Epigenetic editing in prostate cancer: Challenges and opportunities. *Epigenetics.* 2022;17(5):564-88.
63. Dai W, Xu X, Wang D, Wu J, Wang J. Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system. *Oncogene.* 2019;38(21):4110-24.
64. Khalil AM. Cell delivery strategies: Review of the recent developments, challenges, and opportunities. *Int J Appl Sci Res Rev.* 2022;9:60.
65. Schrauben M, Dempster E, Lunnon K. Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease. *Brain Pathol.* 2020;30(5):992-1004.
66. Ueda J, Yamazaki T, Funakoshi H. Toward the development of epigenome editing-based therapeutics: Potentials and challenges. *Int J Mol Sci.* 2023;24(5):4778.
67. Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. *J Control Release.* 2022;342:345-61.
68. Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/Cas9 therapeutics: Progress and prospects. *Sig Transduct Target Ther.* 2023;8(1):36. doi:10.1038/s41392-023-01309-7
69. Sapozhnikov DM, Szyf M. Increasing specificity of targeted DNA methylation editing by non-enzymatic CRISPR/dCas9-based steric hindrance. *Biomedicines.* 2023;11(5):1238.
70. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. *Science.* 2018;361(6405):866-9.
71. Faial T. Engineering epigenetic inheritance. *Nat Genet.* 2023;55(3):357.
72. Takahashi Y, Morales Valencia M, Yu Y, Ouchi Y, Takahashi K, Shokhirev MN, et al. Transgenerational inheritance of acquired epigenetic signatures at CpG islands in mice. *Cell.* 2023;186(4):715-31.
73. Hay AD, Kessler NJ, Gebert D, Takahashi N, Tavares H, Teixeira FK, et al. Mitotic heritability of DNA methylation at intermediately methylated sites is imprecise. *bioRxiv.* 2023:2023-01. doi:10.1101/2023.01.27.525699
74. Huerne K, Palmour N, Wu AR, Beck S, Berner A, Siebert R, et al. Auditing the editor: A Review of key translational issues in epigenetic editing. *CRISPR J.* 2022;5(2):203-12.
75. Alex K, Winkler EC. Comparative ethical evaluation of epigenome editing and genome editing in medicine: First steps and future directions. *J Med Ethics.* 2023;0:1-9.
76. Gruhn WH, Tang WWC, Dietmann S, Alves-Lopes JP, Penfold CA, Wong FCK, et al. Epigenetic resetting in the human germ line entails histone modification remodeling. *Sci Adv.* 2023;9(3):eade1257.
77. Fallet M, Blanc M, Di Criscio N, Antczak P, Engwall M, Bosagna CG, et al. Present and future challenges for the investigation of transgenerational epigenetic inheritance. *Environ Int.* 2023;172:107776.
78. Ghimire BK, Yu CY, Kim WR, Moon HS, Lee J, Kim SH, et al. Assessment of benefits and risk of genetically modified plants and products: Current controversies and perspective. *Sustainability.* 2023;15(2):1722.